GlassScriptPhysician profile
Brady L Olsen
NPI 1902833106
$3,653.00
in general payments reported to CMS, 2019-2025
17 companies · $730 in 2025
The $730 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $517 · 2023: $989 · 2024: $1,136 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.28 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,120.06 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $670.91 | 2022-2025 | |
| Novo Nordisk INC | $459.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $425.71 | 2021-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $317.78 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $210.82 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Corcept Therapeutics | $143.87 | 2023 | Korlym |
| Lilly USA, LLC | $102.03 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $41.71 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $32.91 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $31.00 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $25.46 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.73 | 2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $14.00 | 2021 | |
| Axsome Therapeutics, INC. | $13.81 | 2024 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.15 | 2024 | |
| Glaxosmithkline, LLC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brady Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.